For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results...Continue Reading

This article was originally published by Cancer Therapy Advisor Researchers have used deep whole-genome sequencing (WGS) to identify genomic markers of a “good-risk” group of patients with multiple myeloma with prolonged survival. Specifically, patients found to have a low genomic scar score and chromosome 9 gain had superior outcomes. In the study, researchers analyzed WGS...Continue Reading

This was originally published by AJMC Severe renal impairment (RI) is associated with decreased rates of survival among patients with multiple myeloma (MM), even if renal function is restored with therapy, according to new research. Investigators from Fujian Medical University Union Hospital in China found patients who achieved restoration of renal function recovery had somewhat better odds...Continue Reading

This article was originally published by Cancer Therapy Advisor Receipt of dialysis may be a risk factor for inpatient mortality in patients with multiple myeloma (MM) being treated with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), according to study results published in the European Journal of Haematology. To evaluate inpatient mortality trends, investigators conducted a...Continue Reading

This post was originally published by Myeloma Research News GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approved in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma patients. The marketing authorization application, accepted for review in February, is specific for people with relapsed or refractory disease who were previously treated with an immunomodulatory agent, a proteasome inhibitor, and...Continue Reading

An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. The recommendation by the FDA’s  Oncologic Drugs Advisory Committee is for patients who had at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor,...Continue Reading

This post was originally published by Myasthenia Gravis News A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies against muscle-specific tyrosine kinase (MuSK), a study reports. This unusual case indicates that cancer treatments may mask the symptoms of MG, complicating diagnosis, researchers said. The case was described in the journal BMC Neurology,...Continue Reading

This story was originally published by Targeted Oncology Hearn Jay Cho, MD, PhD, chief medical officer, Multiple Myeloma Research Foundation (MMRF), and associate professor at Mount Sinai Hospital Ruttenberg Treatment Center, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts...Continue Reading

This was originally published by AJMC The bone marrow (BM) microenvironment is believed to play a key role in the evolution of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM), but a new commentary calls attention to another factor that might be involved in the chain of evolution: the gut microbiome. Writing in...Continue Reading

This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ — HealthTree®, the first online portal for multiple myeloma cancer patients to find their best treatment options and help accelerate a cure, today announced the launch of HealthTree University (HTU), the first comprehensive resource that empowers multiple myeloma patients to become experts in...Continue Reading